Health IT

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

A bipartisan bill in Congress aims to give veterans access to emerging mental health treatments, including the novel, non-hallucinogenic compound MEAI.

A new FDA-approved device offers a drug-free alternative for severe rheumatoid arthritis. Rush University is the first in Chicago to implant the system.

With a key drug for a rare disease nearing the finish line, Spruce adds two industry veterans to navigate the high-stakes FDA approval process.

A new data-driven wellness program in Ontario is dramatically reducing cancer risk for firefighters, offering a blueprint for saving lives and city funds.

Estrella Immunopharma unveils promising Phase 1 data for its next-gen T-cell therapy, but can it overcome a crowded market and its own financial hurdles?

New multi-year data for Fabry and Pompe disease therapies from Amicus Therapeutics showcases sustained benefits, offering new hope for long-term patient outcomes.

Omilia has launched a self-learning AI platform promising 'zero-day go-live' for autonomous agents, challenging the entire customer service industry.

New Medicare rules expand access to opioid alternatives, reshaping post-surgery recovery and rewarding companies at the forefront of pain management.

The rehab therapy software giant capped a pivotal year with key AI partnerships, a new executive team, and a major push into remote care, signaling its next era.

An independent analysis shows a specialized OB/GYN staffing model improves maternal outcomes, lowers C-section rates, and delivers a significant return on investment.

Two specialized firms are joining forces, creating BlackBirchSCR to offer a new, unified model for capital raising and strategic communications.

The strategic deal combines sensing systems with core materials, positioning Excelitas as a critical supplier for AI, semiconductor, and defense markets.

A breakthrough in cancer therapy as Avacta's faridoxorubicin proves so safe, regulators have removed historic dosing limits tied to heart toxicity.

Industrial giant AMETEK acquires LKC Technologies, aiming to revolutionize eye care with portable diagnostic devices for early disease detection.

Novo Nordisk exec Karin Conde-Knape joins Valo as CSO, signaling a major validation for AI's role in creating next-generation medicines.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

A new AI-powered blood test from CareDx shows promise in detecting cancer relapse weeks earlier, offering new hope for transplant patients.

Promega's new diagnostic for KEYTRUDA gains NMPA approval, opening doors for targeted solid tumor therapy amid China's growing precision medicine market.

A New Mexico health system is betting on a full-scale AI rollout to reduce doctor burnout, improve patient care, and boost its bottom line.